Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21711901 | 0.82 | ENPP2 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29954372 | 0.82 | ENPP2 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18224040 | 0.81 | NPC1 (0.32) | XDH | |
| SCHEMBL25955725 | 0.78 | UHRF1 (0.42) | PTPN1XDHSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24046844 | 0.77 | SLC6A2 (0.42) | XDHSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29444441 | 0.75 | SLC6A2 (0.37) | XDHSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1054325 | 0.75 | SLC6A2 (0.37) | XDHSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1800081 | 0.75 | EGFR (0.32) | XDH | |
| SCHEMBL29951021 | 0.74 | ACHE (0.39) | PTPN1 | |
| SCHEMBL2703903 | 0.74 | ACHE (0.39) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-102438991-B | Carbinol compounds having a heterocyclic linker | KOWA CO.,LTD. (JP) | 2015-08-26 | — | — | CN | disclosed |
| EP-2426113-B1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | KOWA CO (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8551985-B2 | Carbinol derivatives having heterocyclic linker | KOWA COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| CN-102438991-A | Carbinol compounds having a heterocyclic linker | KOWA CO | 2012-05-02 | — | — | CN | disclosed |
| US-8153634-B2 | Carbinol derivatives having cyclic linker | KOWA COMPANY, LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| EP-2426113-A1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | Kowa Company, Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-102105452-A | Substituted carbinol compound having cyclic linker | KOWA CO | 2011-06-22 | — | — | CN | disclosed |
| EP-2281817-A1 | SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER | Kowa Company, Ltd. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | NR1H2, NR1H3, CCR2 | PTPN1 2803/4885XDH 892/4885SLC6A2 4522/4885 |
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | NR1H2, NR1H3, LDLR | PTPN1 3629/4885XDH 1619/4885SLC6A2 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.